The short version of dual agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-12. Anything still debated is marked as such rather than presented as settled.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
== Pollination and seed development == Pine nuts will not reach full maturity unless the environmental conditions are favorable for the tree and the cone. The time to maturity varies depending on the species. For some American species, development begins in early spring with pollination. A tiny cone, about the size of a small marble, will form from mid-spring through the end of summer; this immature cone will temporarily cease growing and remain dormant until the following spring, then grow again until it reaches maturity near the end of its second summer. The mature piñon pine cone is ready to harvest ten days before the green cone begins to open. A cone is harvested by placing it in a burlap bag and exposing it to a heat source such as the sun to begin drying. It takes about 20 days until the cone fully opens. Once it is fully open and dry, the seed can be easily extracted in various ways. The most common and practical extraction method used is the repeated striking of the burlap bag containing the cone(s) against a rough surface to cause the cone(s) to shatter, leaving just the job of separating by hand the seed from the residue within the bag. Another option for harvesting is to wait until the cone opens on the tree (as it naturally will) and harvest the cone from the piñon pine, followed by the extracting process mentioned above. Fallen seeds can also be gathered beneath the trees.
being aged 45 or older having African American, Alaska Native, American Indian, Asian American, Hispanic/Latino, Native Hawaiian, or Pacific Islander American ethnicity having health conditions such as high blood pressure and abnormal cholesterol levels having a history of gestational diabetes having a history of heart disease or stroke. In addition, some medications and other health conditions can raise the risk.
== Neuropsychopharmacology == Product insert information, accompanying commercial prescription estradiol, indicates it causes depression. In a randomized, double-blind, placebo-controlled study, estradiol was shown to have gender-specific effects on fairness sensitivity. Overall, when the division of a given amount of money was framed as either fair or unfair in a modified version of the ultimatum game, estradiol increased the acceptance rate of fair-framed proposals among men and decreased it among women. However, among the placebo-group "the mere belief of receiving estradiol treatment significantly increased the acceptance of unfair-framed offers in both sexes", indicating that so-called "environmental" factors played a role in organising the responses towards these presentations of the ultimatum game.
==== 2005–2021 ==== While through recent history most designer drugs had been either opioids, hallucinogens, or anabolic steroids, the range of possible compounds is limited only by the scientific and patent literature, and recent years have been characterised by a broadening of the range of compounds sold as designer drugs. These have included a wide variety of designer stimulants such as geranamine, mephedrone, MDPV and desoxypipradrol, several designer sedatives such as methylmethaqualone and premazepam, and designer analogues of sildenafil (Viagra), which have been reported as active compounds in "herbal" aphrodisiac products. Designer cannabinoids are another recent development, with two compounds JWH-018 and (C8)-CP 47,497 initially found in December 2008 as active components of "herbal smoking blends" sold as legal alternatives to marijuana. Subsequently, a growing range of synthetic cannabinoid agonists have continued to appear, including by 2010, novel compounds such as RCS-4, RCS-8, and AB-001, which had never been reported in the literature, and appear to have been invented by designer drug manufacturers themselves. Another novel development is the use of research ligands for cosmetic rather than strictly recreational purposes, such as grey-market internet sales of the non-approved alpha-melanocyte-stimulating hormone tanning drugs known as melanotan peptides.
Electrons are often removed from the electron transport chains to charge NADP+ with electrons, reducing it to NADPH. Like ATP synthase, ferredoxin-NADP+ reductase, the enzyme that reduces NADP+, releases the NADPH it makes into the stroma, right where it is needed for the dark reactions. Because NADP+ reduction removes electrons from the electron transport chains, they must be replaced—the job of photosystem II, which splits water molecules (H2O) to obtain the electrons from its hydrogen atoms.
Sources: en.wikipedia.org
The initial symptoms were similar to other viral diseases that are still extant, such as influenza and the common cold: fever of at least 38.3 °C (101 °F), muscle pain, malaise, headache and fatigue. As the digestive tract was commonly involved, nausea, vomiting, and backache often occurred. The early prodromal stage usually lasted 2–4 days. By days 12–15, the first visible lesions – small reddish spots called enanthem – appeared on mucous membranes of the mouth, tongue, palate, and throat, and the temperature fell to near-normal. These lesions rapidly enlarged and ruptured, releasing large amounts of virus into the saliva. Variola virus tended to attack skin cells, causing the characteristic pimples, or macules, associated with the disease. A rash developed on the skin 24 to 48 hours after lesions on the mucous membranes appeared. Typically the macules first appeared on the forehead, then rapidly spread to the whole face, proximal portions of extremities, the trunk, and lastly to distal portions of extremities. The process took no more than 24 to 36 hours, after which no new lesions appeared. At this point, variola major disease could take several very different courses, which resulted in four types of smallpox disease based on the Rao classification: ordinary, modified, malignant (or flat), and hemorrhagic smallpox. Historically, ordinary smallpox had an overall fatality rate of about 30%, and the malignant and hemorrhagic forms were usually fatal. The modified form was almost never fatal.
== In culture == The jalapeño is a Mexican chili but was designated by the Texas Legislature as the official "State Pepper of Texas" in 1995. In Mexico, jalapeños are used in many forms such as in salsa, pico de gallo, or grilled jalapeños. Jalapeños were included as food on the Space Shuttle as early as 1982. Guinness World Records recognizes Alfredo Hernandes for the most jalapeños eaten in a minute: 16, on 17 September 2006 at the La Costeña Feel the Heat Challenge in Chicago, Illinois. Patrick Bertoletti holds the Major League Eating jalapeño records at 275 pickled jalapeños in 8 minutes on 1 May 2011, and 191 pickled jalapeños in 6.5 minutes on 16 September 2007 in the 'Short-Form'. Joaquín Guzmán, also known as "El Chapo", the leader of the Sinaloa Cartel, operated a cannery in Guadalajara producing "Comadre Jalapeños" in order to ship cocaine to the US. The official mascot of the 1986 FIFA World Cup was Pique, a jalapeño pepper, characteristic of Mexican cuisine, with a moustache, a Colimote sombrero, and Mexican football team colors. Its name comes from picante, a Spanish word meaning "spicy", and was also a pun on the "PK" abbreviation of the football term penalty kick. Pique is also a common Spanish name. September 5th is recognized as National Jalapeno Day.
With intramuscular injection, a dose of 25 mg results in normal luteal phase serum levels of progesterone within 8 hours, and a 100 mg dose produces mid-pregnancy levels of 40 to 80 ng/mL at peak. At these doses, levels of progesterone remain elevated above baseline for at least 48 hours (6 ng/mL at this point for 100 mg), with an elimination half-life of about 22 hours. Due to the high concentrations achieved, progesterone by intramuscular injection at the usual clinical dose range is able to suppress gonadotropin secretion from the pituitary gland, demonstrating antigonadotropic efficacy (and therefore suppression of gonadal sex steroid production). Intramuscular progesterone often causes pain when injected. It irritates tissues and is associated with injection site reactions such as changes in skin color, pain, redness, transient indurations (due to inflammation), ecchymosis (bruising/discoloration), and others. Rarely, sterile abscesses can occur. Large doses of progesterone by intramuscular injection, for instance 100 mg, are associated with moderate-to-severe injection site reactions.
== Industrial synthesis == L-Tyrosine is used in pharmaceuticals, dietary supplements, and food additives. Two methods were formerly used to manufacture L-tyrosine. The first involves the extraction of the desired amino acid from protein hydrolysates using a chemical approach. The second utilizes enzymatic synthesis from phenolics, pyruvate, and ammonia through the use of tyrosine phenol-lyase. Advances in genetic engineering and the advent of industrial fermentation have shifted the synthesis of L-tyrosine to the use of engineered strains of E. coli.
Free Fluid Mechanics books Annual Review of Fluid Mechanics. Archived 2009-01-19 at the Wayback Machine. CFDWiki – the Computational Fluid Dynamics reference wiki. Educational Particle Image Velocimetry Archived 2017-08-03 at the Wayback Machine – resources and demonstrations
Sources: en.wikipedia.org
=== Radio === Albany has eight different radio stations that are either broadcast or have offices within Albany and many others that serve the area. the FM stations are, 107.9FM KHPE that uses the tagline (HOPE-FM) which is a Christian contemporary music radio station, and 99.9FM KRKT-FM, a country radio station that both broadcast from Albany. There is also 101.5FM KFLY, which is based out of Eugene, Oregon, but maintains an office in the Albany area. Along with the FM stations there are five AM stations. 790 AM KWIL, is the AM version of KHPE (107.9FM). The others range from adult standard such as KSHO (920 AM), comedy radio and Seattle Mariners baseball games KTHH (990 AM), to sports KEJO (1240 AM), and KGAL (1580 AM) the local news and talk radio station.
=== Market value === American Metal Market predicted in 2001 that the use of nickel-free Nordic gold in Euro coinage would impact the nickel market, estimating 50,000 to 70,000 tonnes of nickel would be scrapped from obsolete coinage in 2002. The market price of nickel surged throughout 2006 and the early months of 2007; as of April 5, 2007, the metal was trading at US$52,300/tonne or $1.47/oz. The price later fell dramatically; as of September 2017, the metal was trading at $11,000/tonne, or $0.31/oz. During the 2022 Russian invasion of Ukraine, worries about sanctions on Russian nickel exports triggered a short squeeze, causing the price of nickel to quadruple in just two days, reaching US$100,000 per tonne. The London Metal Exchange cancelled contracts worth $3.9 billion and suspended nickel trading for over a week. Analyst Andy Home argued that such price shocks are exacerbated by the purity requirements imposed by metal markets: only Grade I (99.8% pure) metal can be used as a commodity on the exchanges, but most of the world's supply is either in ferro-nickel alloys or lower-grade purities. In 2024, the average nickel price is estimated by the London Metal Exchange (LME) to be $15,328 per metric ton, 7.7% less than it was in 2023. At the end of 2024, the price reached its lowest levels since 2020.
Compulsion Games said they were prepared to offer refunds even to Kickstarter backers from Australia should they be unable to achieve a rating. The Australian Ratings Board agreed to review their classification, offering interested parties to also reply in standing for reclassification of the game during the month of July 2018. On 3 July, the Board announced that they had reclassified We Happy Few with an R18+ rating, still warning consumers of its drug-use mechanic, but otherwise clearing the title to be sold within Australia. The full game was released for PlayStation 4, Windows, and Xbox One on 10 August 2018. On 27 November 2018, Dark Horse Comics released a 192-page book titled The Art of We Happy Few.
In February 2022, Bukele accused United States president Joe Biden of "crying wolf" about a Russian invasion of Ukraine. Bukele did not comment on the invasion when it began later that month, posting instead on Twitter about bitcoin and bonds. Throughout 2022, El Salvador abstained from votes on United Nations resolutions condemning the Russian invasion of Ukraine. Bukele condemned the 7 October attacks, describing Hamas as "savage beasts" who "do not represent the Palestinians", comparing the group to MS-13. He tweeted that "the best thing that could happen to the Palestinian people is for Hamas to completely disappear". In March 2024, Bukele offered to send a mission to Haiti to "fix" the country's gang war with United Nations Security Council support. In October 2024, El Salvador agreed to provide soldiers to conduct street patrols and aerial surveillance for the Multinational Security Support Mission in Haiti, and the first Salvadoran soldiers arrived in Port-au-Prince on 3 January 2025. In March 2026, Bukele attended the Shield of the Americas summit in Miami along with several other Latin American leaders.
Concert dates in support of the album were later canceled due to Sheik seeking treatment for alcohol addiction. A remixed version of the album was released the following year. Sheik released the studio album Legerdemain in October 2015.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.